The latest instalment of the FT’s Digital Health Europe Summit will be held in Berlin and will home in on the approaches, investment and frameworks needed to implement connected health solutions. Health leaders will share their experiences and vision for delivering digitally-driven integrated care.
FT Digital Health Summit Europe
From Fragmentation to Integration
Charité University Medical Center
McKinsey & Company
All sessions will be delivered in English, unless otherwise stated.
"Excellent speakers and well organised. I will definitely come again.” Nick Hirst, CIO, NIHR CRNCC
“Excellent 1-day snapshot of the key issues in digital health.” Ed Currie, Smart Health Ambassador, TM Forum
“Thanks a lot for the opportunity to be a part of this extraordinary event. It really has been a pleasure. Looking forward to see you again in the future” Karl Pall, Director, Google
“Excellent platform to have an open, frank discussion in an environment that is so traditional and fixated, yet cutting-edge in so many ways.” Khilona Radia, CEO, Antrum Biotech
“High quality speakers” Lars Dahle, CEO, Dignio
Fragmentation in healthcare and the lack of coordination between departments and services are major barriers to be overcome as the transformation of health gathers pace across Europe. Digital technologies have the power to connect and integrate isolated and disparate services and deliver more intuitive and coordinated patient experiences. However, with the huge number of new technologies, devices and applications, and growing amounts of data, there is the risk that digital innovations will add to the fragmentation if the issues of interconnectivity, security and access are not addressed.
The keynotes, interviews, panels and debates will explore how technology can help to unite the fragments, strengthen systems, and improve patient experiences and outcomes throughout the continent.
Vasant (Vas) Narasimhan has been Chief Executive Officer of Novartis since February 2018. Dr Narasimhan previously was Global Head of Drug Development and Chief Medical Officer for Novartis. He has also served as Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.
Dr Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.
Penny Dash leads McKinsey’s healthcare work across Europe with a focus on redesigning services to improve quality and efficiency of care delivery.
Penny has over 20 years experience in health care consulting and also spent time as Head of Strategy for the NHS. From 2004 to 2006 she was a non-executive Director of Monitor, the Independent Regulator for Hospitals in England and served as a Trustee and Vice Chairman of the King’s Fund from 2006 to 2014.
Penny originally trained as a doctor in Cambridge and London and is a Fellow of the Royal College of Physicians of London. She has a MSc in Public Health
Medicine and a MBA from Stanford Business School where she was a Fulbright Scholar.
Xavier Prats Monné
Xavier Prats Monné has been the Director-General for Health and Food Safety of the European Commission since September 2015. He is responsible for EU policies and programmes in health and food safety, including the promotion of public health, the assessment of national healthcare systems' performance, pharmaceutical legislation, animal health and welfare, as well as the strengthening of Europe's capacity to deal with crisis situations in human health and the food sector. He previously served as Director-General for education and culture and as Director for employment policy.
He holds degrees in Social Anthropology from the Universidad Complutense (Madrid, Spain); in Development Cooperation from the International Centre for Advanced Mediterranean Agronomic Studies (CIHEAM; Paris, France); and in European Studies from the College of Europe (Bruges, Belgium), where he graduated first of the Class of 1981-82 and served as assistant professor.
Milind Kamkolkar is the CDO of Sanofi, a company focused on empowering lives through human health. Milind’s focus is driving and transforming Sanofi from a data generation organization to an insights generating organization where data is a monetizable asset class on par with product and shareholder value.
Milind joined Sanofi from a career spanning big pharma (Novartis), big and boutique consulting (Cognizant and PA Consulting), and numerous technology and software startup companies focused on health, technology and data mining blending insights and approaches across industries to solve complex human health problems at scale.
Milind is a featured speaker and thought leader in Digital Health, AI & Big Data, serves as a Board Advisor and mentor to 3 exciting startups hacking education/mental health, deep learning for research technologies, Honorary Lecturer for physician entrepreneurship at BartsX, Faculty at Exponential Medicine and Special Advisor to the UN Global Sustainability program.
Carina is a Partner at Episode1 Ventures, where she invests across the latest trends in: health technology, computational biology, AI, VR, blockchain and robotics. Carina spent 5 years in Silicon Valley, where she founded HelixNano with a team from MIT – applying AI to genetic data. Carina is an alumnus of YCombinator, Singularity University and Oxford University. She sits on the curatorial committee of the ScienceGallery in London. Previously, Carina was an Entrepreneur-in-Residence at Johnson&Johnson Innovation and an M&A advisor with Goldman Sachs.
Henk de Jong
Prof Dr Erwin Böttinger is Professor for Digital Health - Personalized Medicine and Head of Digital Health Center at the Digital Engineering Faculty of the Hasso Plattner Institute (HPI) GmbH at the University of Potsdam. He is the founding director of the HPI Digital Health Center. From November 2015 to July 2017 Prof Dr Böttinger was the CEO of the Berlin Institute of Health (BIH). Prof Dr Böttinger is considered an international expert in personalized medicine and digital health, in particular for his performance as founding director of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai in New York, USA, from 2005 to 2015.
As General Manager of Health at Microsoft, Neil Jordan is chief strategist for Health industry initiatives worldwide. Neil defines, drives, and articulates the Microsoft vision for the future of Healthcare and how Microsoft products, technologies and partner solutions make it a reality.
Neil leads the collaboration with a global ecosystem partners to provide innovative solutions that meet the specific needs of customers working to deliver better health outcomes for more people. He has driven consistent growth of this multi-billion-dollar business. During his time in the US Neil has also generated 3 health-related patents including one co-authored with Bill Gates.
Previously, Neil was the head of Healthcare at Microsoft UK where he was responsible for leading strategic operations and senior customer and partner relationships. He led interaction with the NHS National Programme for IT, the largest ever civil IT procurement and the largest application delivery in Microsoft’s history, including managing close engagement with the UK government.
Neil joined Microsoft in 2000 as a telecommunications solutions sales manager where he was responsible for market entry into the areas of mobility, hosting and web services solutions in the UK. Prior to joining Microsoft, he worked at IBM Software Group UK where he was the EMEA strategic alliances manager.
Christian Lautner is Co-founder and Managing Partner at Flying Health, focusing on serious digital health technologies i.e. digital biomarkers and digital therapies.
Previously, he co-founded one of the first German doctors rating platform imedo.de and later joined qualitaetskliniken.de as CEO to work towards comparability of hospital quality accessible for everyone via digital devices.
Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.
David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.
Mr Crow has an MA in English Literature from the University of Glasgow.
Agenda - 19th Jun
8:00amRegistration and networking
8:50amChair’s opening remarks
9:00amKeynote address: The digital agenda in Europe - creating a unified platform for health
9:30amHealth leaders’ panel: Perspectives on integrated healthcare delivery
Healthcare services across Europe are facing challenges around cost, security, engagement and integration. During this opening panel, European health leaders will share perspectives on overcoming vulnerabilities and discuss best practices for realising a smooth transition to ‘mainstream’ digital health.
- Ways of creating smarter systems that are useful, usable and used. How far, how fast and at what scale can the transition to digital health be made?
- What are the difficulties of combining technologies from different providers into one integrated healthcare experience for the patient?
- How is the digital transition being paid for?
- How can healthcare professionals keep up with the new wave of technological innovation?
- Initiatives to equip the workforce with skills, knowledge and experience
10:20amKeynote Interview: Regulation in the digital era of health
11:00amDiscussion Panel: Breaking down the data silos
Historically, the fragmented nature of health systems in Europe has made it difficult to share information, and with more and more data sets being created in isolation, the proliferation of big data is adding to the fragmentation. This session will explore ways of tackling the integration challenges to ensure that the data acquired by doctors, hospitals, laboratories and technology companies is shared and exploited securely and for the benefit of the patient.
- Who owns and controls the data and how can it be shared safely and flow freely across the health spectrum?
- Building transparency and trust and the impact of changes in data protection legislation
- Creating efficient digital pathways and getting data to where the decision making processes are taking place.
- To what extent can the patient be put in control of their own information?
- What can be learnt from other industries such as banking and retail about standardising and integrating data across platforms?
11:50amInvestment Panel: Balancing risk and opportunity
In the fast-evolving digital health landscape, the pressure is on for technology developers to differentiate themselves from the competition as they seek to attract investment capital. This session will consider the extent to which digital health is continuing to be fertile ground for investment andwhich opportunities are exciting investors in 2018.
- Patterns of investment: which health-tech and digital products are showing the best ROI?
- What are investors in tech-enabled health looking for?
- The outlook for consolidation: M&A activity and impact.
- What will investment look like post-Brexit?
12:40pmFireside chat: Delivering value-based care
2:00pmDigital health dialogue: The human approach to disruption: integrating the voice of the patient
High on the agenda is the need to build trust and engage patients in the transformation of healthcare. Understanding what the individual wants and integrating their voice into the development phase of digital technologies and services will help to deliver more intuitive experiences and enable patients to take control of their health, diagnosis and treatment. This dialogue will focus on how collaboration is driving acceptance and engagement and putting the person at the centre of personalised health.
2:30pmSpecial focus: The digital reinvention of clinical trials
Digital technologies are starting to prove their worth in the quest to tackle costs and inefficiencies and streamline the clinical trial process. Social media, big data, wearables and mobile devices are transforming the collection and analysis of patient information. Going forward, how can clinical trials be further moved into the digital age?
- In what ways are pharma companies adapting their R&D processes and accelerating progress towards digital drug discovery?
- How can AI and machine learning be used to provide better insights, analysis and understanding of data?
- How is regulation evolving and what barriers does it pose?
- Could trials be conducted entirely using measurements taken with remote devices? What would this do to costs and patient engagement? And what would it mean for trial design?
3:40pmIn Conversation with the FT: Coming up with the evidence
How to generate evidence on the effectiveness of digital technologies
4:00pmTechnology Spotlight: At the cutting edge of health transformation
This series of brief presentations and quick-fire interviews will shine a spotlight on the innovators and trailblazers who are broadening the frontiers in prevention and treatment. Companies at the cutting edge of digital health will present what their technologies offer in terms of impact on patients and potential returns on investment and discuss their plans for market adoption and integration.
- Assess how patients are being empowered and further involved in the transformation of healthcare
- Hear how collaborations between pharma and big tech are enriching the commercial viability of digital health
- Meet and greet with the full array of industry stakeholders, from healthcare to technology, pharma to start-ups, regulation to government
- Identify solutions in overcoming cyber security threats in digital health
- Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare
FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.
The FT Digital Health Summit Europe will be attended by:
- Pharmaceutical and biotechnology companies
- Healthcare Providers
- Medical Device manufacturers
- Health insurers
- Investment banks
- Hospital Management
Early Bird Ticket (ends 15 March)
Standard Summit Ticket
- Gain access to 150 Senior Executives from the Digital Health Industry, who will be attending the event;
- Brand alignment with the FT and its unrivalled credibility;
- Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
- Benefit from sustained international visibility through our advertising and marketing campaigns
Commercial Manager, Global Industries
Presented By (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. Providing essential news, comment, data and analysis for the global business community, the FT has a combined paid print and digital circulation of 840,000. Mobile is an increasingly important channel for the FT, driving more than half of total traffic.